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Abstract
Spasticity is a very troublesome symptom, which causes further deterioration in physical disability and in
many cases precludes effective treatment. The aim of this paper is to recall different methods for treating
spasticity, with particular consideration of the modern method of employing a baclofen pump with a patient
who had suffered trauma to the cervical spinal cord.
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Introduction
Spasticity is a very troublesome symptom, which
causes further deterioration in physical disability and
in many cases precludes effective treatment. The
aim of this paper is to recall different methods for
treating spasticity, with particular consideration of
the modern method of employing a baclofen pump
with a patient who had suffered trauma to the cer-
vical spinal cord.
According to Lance's classical definition, spasti-
city is a motor disorder characterized by a velocity-
dependent increase in tonic stretch reflexes (muscle
tone), resulting from the stretch reflex as one com-
ponent of upper motor neurone syndrome [1, 2].
Its modification by Young and Sheen points to
cortical control of muscle tension involving pyrami-
dal, reticulospinal, vestibulospinal and rubrospinal
tracts, as much as reflex control by alpha motor
neurones, excitatory and inhibitory interneurones
and polysynaptic reflexes. The spinal control mecha-
nisms, such as the Renshaw cell system and Golgi
tendon cells, take part in controlling and also in
supraspinal actions such as cerebellum and reticu-
lar formation, the cerebral cortex and the autono-
mic system [2, 3].
Spasticity results from an increased activity of
the gamma motor system. Thus, it is the result of
distortion in balance between mechanisms activa-
ting and inhibiting alpha and gamma motor neu-
rones in the spinal cord. It can also be explained by
the unlocking of control of spinal reflexes by su-
praspinal sites, which means the withdrawal of the
influence of gamma motor neurones by inhibitory
centres. This leads to increased activity of muscle
spindles. A typical symptom of spasticity is called
the clasp-knife response [2].
Soon after spinal cord injury, there is an initial
phase of spinal shock, a term first used by M. Hall in
1841, which is characterized by the loss of all refle-
xes below the injured segment. At the time of lo-
sing cortical control over the spinal cord there is
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a great increase in the activity of motor neurones.
This presents itself in spasm: prolonged, uncon-
trolled and excessive contraction of skeletal mus-
cles and pathologically exaggerated responses to
every kind of stimulation. Subsequently, an increased
and greatly spreading muscle contraction in res-
ponse to stretching appears. Clinically, it is mani-
fested by hyperactive reflexes: increased muscle ten-
sion due to passive movement. The spinocerebellar
tract, which normally plays an important role in
passing information from the peripheral to the cen-
tral nervous system, becomes totally useless as the
whole spinal organization loses meaning. Urinary
bladder distension, skin irritation, the blowing of
cold air, or any other stimulus, provokes the same
response, independent of its location or significance
to the organism. All stimuli may elicit an increase in
spasticity. Loss of control by descending tracts leads
to hyperactivity of interneurones with simultaneous,
spontaneous, persistent neuronal firing. Freed from
inhibitory and coordinating influence, the mecha-
nisms within the gamma loop become excessively
activated. Fast passive movement is met by increas-
ing resistance which suddenly melts away — hence
the term clasp-knife reflex. The reticulospinal tract,
being the stretch reflex activator, also plays a role in
sustaining spasticity. Increased muscle tension is
accompanied by an exaggerated stretch reflex, es-
pecially within flexor muscles. Spastic muscle tone
in paralyzed patients, with a tendency to flexion
and adduction in the hip joint and overflexion at
the knee, makes caring for them even more diffi-
cult. Other symptoms of spasticity include the fol-
lowing: exaggerated deep tendon reflexes, patho-
logical reflexes, pathological synkinesis and clonus,
autonomic system hyperactivity, paresis, muscle
palsy, increased muscle weakness, lack of move-
ment precision and loss of superficial reflexes [2, 4].
Spastic jerks may sometimes cause the patient
to fall from a bed or wheelchair. Gradual limitation
of movement within joints and contractures follows.
Increased spasticity predisposes the patient to bed-
sores resulting from skin abrasions during involun-
tary limb movements. A considerable level of spas-
ticity is a very annoying symptom, further exacer-
bating physical disability and quality of life. Thus,
prevention or treatment of spasticity becomes one
of the most important elements in the rehabilita-
tion of patients with central paralysis. The treat-
ment is aimed not only at increasing physical condi-
tion and a maximal reduction in disability, but also
at prevention of complications such as bedsores,
periarticular ossification, contractures, joint insta-
bility and luxation, foot deformities, and dysfunc-
tion of urinary and digestive systems. Proper treat-
ment of spasticity also decreases pain sensations
related to spasms and makes it easier to care for a
patient [1, 2, 5].
One of the most modern methods of treatment
for spasticity is therapy based on the subarachnoid
infusion of baclofen. A surgically implanted dosi-
meter automatically dispensing regularly-spaced
doses guarantees constant drug concentration in
the spinal canal, which is necessary for the treat-
ment to be effective. Side effects with baclofen treat-
ment, such as hypotension, drowsiness, dyspnoea,
coma, photophobia, respiratory disorders, convul-
sions, pain at the site of pump implantation and
infection, are rare. Any serious symptoms most com-
monly result from a badly-set dose or simply in the
overdosing of baclofen [5].
Case report
A 13-year-long observation of a patient, follow-
ing injury to the cervical spinal cord, implanted with
a baclofen pump in order to decrease spasticity of
the lower limbs.
On November 13, 1994 the patient, now 52-years-
-old, fell from a height of 1.5 m and suffered trauma
to the spinal cord at the C6–C7 level. Immediately
after the injury he was treated surgically by stabilizing
with the use of a titanium plate. The injury left him
with paralyzed lower limbs, upper-limb paresis (P > L)
with bladder and anal sphincters also paralyzed.
Due to a great degree of spasticity in the lower
limbs, the patient stayed unresponsive to large doses
(150 mg per day) of baclofen taken orally and suf-
fered from a great deal of pain (NRS: 8). The deci-
sion to implant the baclofen pump was taken in
order to free the patient from this. Constant infu-
sion of baclofen to the subarachnoid space is indi-
cated in cases of lack of response or side effects
from oral treatment with baclofen and positive re-
sults from a baclofen test. The baclofen test is based
on injecting single doses (25–100 mg) of baclofen
into the subarachnoid space. The interthecal meth-
od of injecting baclofen allows for reducing the drug
dose more than 100 times with good therapeutic
results [6]. The described patient met all the crite-
ria. After receiving positive baclofen test results the
procedure of pump implantation was performed
on March 19, 1996 at the City Hospital in Koblenz,
which was one of the first centres in Europe to im-
plant baclofen pumps. The model ARROW-THEREX
3000 was implanted by Professor Muller. A sub-
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arachnoid catheter was inserted at the L3–L4 level
ending at T6. The capacity of the implanted pump
is 30 ml and the optimal time required to empty it
is 50 ± 3 days. The initial dose of baclofen at the
time of implantation was 14 mg and it is presently
set at 18 mg. The very small increase in the required
dose of baclofen shows a lack of tachyphylaxis to
the drug applied through the spinal canal.
Baclofen is a spasmolytic drug, derivative of
GABA, and is commonly applied in the treatment of
spasticity. It decreases skeletal muscle tone by in-
hibiting mono- and polysynaptic reflexes in the spi-
nal cord, which is its site of uptake. The detailed
mechanism of the action of baclofen is unknown
but its relaxing effect is based on interaction with
the alpha motor system and dependent on decreas-
ing activity in the gamma motor system. Baclofen
does not decrease conductivity within the neuro-
muscular junction or sensitivity of the sensory end-
ing of muscle spindles. The oral dose varies from 10
to 150 mg per day. Baclofen is well tolerated but its
side effects include dizziness, vertigo, muscle weak-
ness, tiredness, headaches, sleeplessness, speech
disorders, blurred vision, hypotension, nausea, con-
stipation, skin rash, excessive sweating, increased
acivity of aminotransferases and alkaline phos-
phatase, increased glucose level and, rarely, depres-
sion. Contraindications to treatment with baclofen
include hypersensitivity to the preparation, or pep-
tic or duodenal ulcers. Caution is advised while treat-
ing psychiatric patients with schizophrenia or psy-
chosis, epilepsy, stroke, and those with renal or li-
ver failure. The direct infusion of the medication to
the subarachnoid space through the intrathecal pump
allows binding of the drug particles with the recep-
tors in the dorsal roots, permitting treatment with
100 times lower doses compared with those admin-
istered orally, and it results in a weak penetration of
baclofen through the blood-brain barrier. At present,
baclofen is available as an injection preparation un-
der the names of Loresal and Kemstro [7–10].
From the beginning of our patient's treatment,
pump refilling was performed in our centre. Twice
during our 13-year-long care of the patient, he was,
due to urinary or respiratory infections, staying in
other hospitals at the time of the required pump
refilling. Since both hospitals had Pain Centres, on
site doctors attempted to refill the pump.  Unfortu-
nately, the pump was damaged each time and ba-
clofen intoxication followed, requiring mechanical
ventilation and consequent pump replacement. The
symptoms of baclofen intoxication included sud-
den respiratory failure, depressed states of con-
sciousness, muscle flaccidity and fever. Damage to
the pump resulted from employing incorrect need-
les and poor procedural technique. The pump im-
plantation took place in October of 1996 and Au-
gust of 1998.
Due to the poor penetration of baclofen through
the blood-brain barrier, the only effective way of
applying the drug is directly to the cerebrospinal
fluid. The most convenient method is constant infu-
sion through the pump. In order to ensure its prop-
er function it is required that the procedure of refill-
ing is performed in a sterile environment and that
proper needles are used. The best needles used for
refilling are either the Hubner type needles or Port
22G, which have been specially ground to avoid
membrane rupture. For the best results, the refilling
should be performed in one centre.
Final diagnosis
Injury to the cervical spine at the C6–C7 level in
November, 1994. Paraplegia. Neurogenic bladder.
Cervical spine stabilization complicated by broncho-
oesophageal fistula. Reconstructive operation of
broncho-oesophageal fistula and pleural empyema
in May, 1995. Resection of left inferior pulmonary
lobe in January, 1996. Chronic bronchitis. Long-term
treatment with baclofen. Baclofen pump implanta-
tion in March, 1996. Damage to the pump compli-
cated by intoxication with baclofen and pump re-
placement in October, 1996 and August, 1998. HepB
infection in 2000. Chronic urinary infection. Degen-
erative joint disease of spine and main joints, espe-
cially the hip. Obesity. Chronic constipation.
Discussion
Methods of treatment leading to the improve-
ment or elimination of spasticity can be divided
into three groups: physiotherapy, pharmacology and
surgical. Physiotherapy is aimed at decreasing mus-
cle tone, blocking pain receptors, decreasing im-
pulse flow to the CNS and temporary weakening of
nerve conduction [2, 3].
Pharmacological treatment includes preparations
with general activity, such as baclofen, tolperisone,
dantrium, mephenesin, myolastan, methocarbam-
ol, pridinol, phenoprobamat and benzodiazepines
and preparations acting directly on the spinal cord,
nerve roots, motor points and peripheral nerves.
Pharmaceuticals administered orally decrease the
tonus of all muscles, including the non-spastic ones.
Their side effects include a deterioration in cogni-
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tive functions, drowsiness, weakness, confusion,
vertigo, phlebitis or liver damage [2].
In patients suffering from a degree of spasticity
great enough to prevent normal functioning, fol-
lowing the unsuccessful employment of all non-in-
vasive methods of treatment, a surgical interrup-
tion of the reflex arch can be conducted. These sur-
gical methods usually involve mielotomy, rhizoto-
my, DREZ-tomy or procedures on tendons and mus-
cles [1, 2, 11].
Among the various methods of treating spastic-
ity of different origin (spinal, cerebral or combined),
there is a therapy based on the subarachnoid infu-
sion of baclofen with the use of a pump. The me-
thod was first described in 1984 and is now widely
employed in the treatment of spasticity due to scle-
rosis multiplex, spinal cord and cerebral injuries,
infantile cerebral palsy and in dystonias.
The baclofen pump is of little more than 7 cm
diameter (Figure 1AB) and is implanted in the ster-
ile environment of an operating room. The pump is
placed in a subcutaneous pocket, at a depth of 4
cm, on the front of the abdominal wall. It is con-
nected with a catheter placed in the subarachnoid
space, through which a permanent flow of baclofen
ensures a constant concentration of the drug inter-
thecally (Figure 2). The next step is to establish the
minimum effective dose of baclofen. Immediately
after the implantation procedure the patient is ex-
amined in terms of respiratory rate, muscle tone,
presence of spasticity and involuntary movements.
The spasticity assessment is most commonly based
on the Ashworth Scale, characterized by a high de-
gree of data compliance and repeatability. Since
1987, a modified Ashworth Scale [12] has become
more common for assessing spasticity (Table 1). This
method of treatment is combined with the inten-
sive education of patients and their families rela-
ting to the handling of the implanted pump. Physi-
cal rehabilitation reinforced by educating the pa-
tient in this subject takes place concurrently. Since
the pump is a pneumatic device lacking electronic
parts, its expected lifespan is about 25 years, pro-
vided it is not damaged at the time of repeated
refilling through poor procedural technique or the
use of incorrect needles (Figure 3).
The baclofen pump has been in use in Poland for
the last few years in cities such as Poznań, Szczecin,
Gdańsk, Kraków and Zakopane. Until recently, the
NFZ had not been refunding the costs related to the
pump implantation, since the equipment itself is
quite expensive (accounting for 30,000 zl) with the
cost of medication in addition to this. Gathering
such funds was impossible for many patients. In-
creasing acceptance of this procedure by the NFZ
has made a real breakthrough in accessibility of this
method for patients with spinal injury, MS and in-
fantile cerebral paralysis, and all others with proper.
Figure 1AB. Baclofen pump
B
Figure 2. Catheter placed in the subarachnoid space.
Permanent flow of baclofen ensures a constant
concentration of the drug interthecally
Septum
Catheter
A
Pump
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The baseline for the lack of effective and long-
lasting methods of treatment for spasticity is the
complexity of its pathophysiology.  Prior to making
decisions about implanting the pump, it is impera-
tive to examine the patient's physical condition care-
fully and thoroughly consider the indications and
contraindications for this kind of treatment. A di-
rect indication is the positive result of the baclofen
test or a decrease in spinal spasticity by 2 points
and cerebral spasticity by 1 point on the Ashworth
Scale. Patients who meet the following criteria would
qualify for pump implantation:
1. Severe spasticity due to infantile cerebral paraly-
sis, multiple sclerosis or spinal cord injury.
2. Spasticity greatly limiting the patient's daily func-
tioning and self-caring.
3. Improvement in functioning and self-caring can
be prognosticated.
4. Spasticity is prolonged and has lasted more than
12 months.
5. The patient is over 4 years-old.
6. The implantation procedure can be performed
at least 12 months after any previous surgery.
7. The patient does not tolerate, or spasticity is
resistant to, orally administered drugs.
8. Any disorders within the spinal canal have been
excluded.
Table 1. Modified Ashworth Scale for grading spasticity
0 No increase in tone
1 Slight increase in muscle tone, manifested by a catch and release or minimal resistance at the end
of the ROM when the affected part(s) is moved in flexion or extension
1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout
the remainder (less than half) of the ROM
2 More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
3 Considerable increase in muscle tone, passive movement difficult
4 Affected part(s) rigid in flexion or extension
Figure 3. The pump filling up technique
9. The patients and their families are motivated
and cooperate with medical personnel while de-
ciding on this kind of treatment.
10.The patient's place of living is less than 200 km
from the centre taking care of the patient.
11.Stabilized medical condition.
Significant contraindications to this kind of treat-
ment are local or general infections, liver or kidney
failure, allergy to baclofen, pregnancy, menopause,
condition after cerebral haemorrhagic stroke, diges-
tive system disease, and lack of cooperation. A more
controversial contraindication is the patient’s ha-
ving a life expectancy of less than 1 year [13].
New longer-lasting and more effective methods
of treatment for spasticity should still be searched for.
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